Table Graph
      published meta-analysis   sensitivity analysis   studies

lopinavir/ritonavir, ribavirin and interferon beta-1b in COVID-19 mild to moderate - Summary of results

OutcomeTE95% CInkI2ROBPub. bias deathsdetailed resultsHung et al., 2020 0.47 [0.01; 24.30] 0.47[0.01; 24.30]Hung et al., 202010%127NAnot evaluable clinical improvementdetailed resultsHung et al., 2020 3.92 [1.66; 9.24] 3.92[1.66; 9.24]Hung et al., 202010%127NAnot evaluable clinical improvement (time to event analysis only)detailed resultsHung et al., 2020 3.92 [1.66; 9.24] 3.92[1.66; 9.24]Hung et al., 202010%127NAnot evaluable viral clearance detailed resultsHung et al., 2020 4.37 [1.86; 10.25] 4.37[1.86; 10.25]Hung et al., 202010%127NAnot evaluable viral clearance (time to event analysis only)detailed resultsHung et al., 2020 4.37 [1.86; 10.25] 4.37[1.86; 10.25]Hung et al., 202010%127NAnot evaluable serious adverse eventsdetailed resultsHung et al., 2020 0.23 [0.01; 7.12] 0.23[0.01; 7.12]Hung et al., 202010%127NAnot evaluable0.010.01.0relative treatment effectwww.metaEvidence.org2024-04-27 16:27 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 90 - treatments: 554 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons